Details:
ALE.F02 is a mAb which works by targeting Claudin-1 (CLDN1), designed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs and is currently under development for kidney, lung, and liver fibrosis.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing April 13, 2023
Details:
ALE.F02 is a highly selective anti-CLDN1 mAb that recognizes pathological overexpressed and conformation-dependent CLDN1 epitopes on transformed epithelial cells and is being investigated for the treatment of fibrotic disease in the kidney, lung and liver.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
VS-01, is a first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development as a potential first-line therapy for the timely recovery of ACLF and UCD.
Lead Product(s): VS-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VS-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Genfit
Deal Size: $107.6 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 19, 2022
Details:
Data showing both single and repeated intraperitoneal administrations of VS-01 reduced the concentration of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) related to ACLF.
Lead Product(s): VS-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VS-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Alentis dosed first cohort of healthy participants in Phase 1 clinical trial of ALE.F02, a monoclonal antibody highly selective for Claudin-1 for treatment of liver and kidney fibrosis. ALE.F02 has demonstrated compelling safety and efficacy in preclinical patient-derived models of liver and kidney fibrosis.
Lead Product(s): ALE.F02
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ALE.F02
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
VS-01 is a potentially lifesaving, multi-organ support therapy that aims to timely reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxins following paracentesis.
Lead Product(s): VS-01
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: VS-01
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021